Thus, CRC is another example where Wnt pathway antagonism, either by biologics targeting the Frizzled receptors or their secreted agonists WNT or RSPO, displays synergistic anti-tumor activity in combination with a taxane and results in better combination activity than other types of chemotherapy. The gene discussed is RSPO1; the disease is neoplasm.